I just read an article that describes the market for “Nicotine De-Addiction Products.” For the purposes of this article they include Nicotine Gums, Patches, Lozenges, Inhalers, Sprays, Sublingual Tablets, Zyban, Chantix/Champix, E-cigarettes.
2012 $5.1 Billion with a giant B!
2019 (projected) $16.02 Billion!
That’s a market increase of 18.7% in a short 7 years!
So where is all that money going for “smoking de-addiction products”?
NRTs were worth 995.5 million in 2012. Increased promotional activities and effective distribution is expected to boost their market growth in the near future. The major players in the NRT products market include Johnson and Johnson, GSK, Cipla and Novartis.
Smoking cessation pharmaceuticals market is expected to witness a decline in revenue across the globe, by the end of 2019. Zyban (bupropion) lost it’s patent in 2013 and Chantix/Champix (varenicline) will lose theirs in 2018. The leading players in the drug therapy market are GSK and Pfizer.
The e-cigarette market has posed a challenge to smoking cessation products as well as to the tobacco cigarette business. The global e-cigarettes market was worth 1.662.5 billion in 2012. Lorillard, NJOY and VMR products LLC are some of the major players in the e-cigarettes market.
Big Tobacco got into the game when Lorillard acquired Blu, an e-cigarette brand, and demonstrated its economic power. NJOY has the largest portion of the market and has been in the e-cig business since 2006. The first thing they did was to hire former tobacco marketers to show them how to convince the consumer. VMR is America’s largest volume online retailer of electronic cigarettes in a strategic partnership with National Tobacco Company (NTC), distributor of the iconic Zig-Zag and Beech-Nut brands.
My conclusions?
You can either go with the same pharmaceuticals that sell me my COPD medicines
OR
You can go with the newest industry knee deep in BIG TOBACCO
OR
You can be a Smart Turkey!
I have more trust in ME that I do in folks who want to see me sick and/or hooked!
